ID   CL-14
AC   CVCL_1979
SY   CL14
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03473569
DR   BioSample; SAMN10988457
DR   cancercelllines; CVCL_1979
DR   Cell_Model_Passport; SIDM01491
DR   ColonAtlas; CL14
DR   DepMap; ACH-000342
DR   DSMZ; ACC-504
DR   DSMZCellDive; ACC-504
DR   GEO; GSM513932
DR   GEO; GSM514184
DR   GEO; GSM886934
DR   GEO; GSM888000
DR   GEO; GSM1448171
DR   IARC_TP53; 28287
DR   LiGeA; CCLE_737
DR   PharmacoDB; CL14_207_2019
DR   Progenetix; CVCL_1979
DR   Wikidata; Q54813473
RX   PubMed=15316659;
RX   PubMed=19003396;
RX   PubMed=22460905;
RX   PubMed=25926053;
RX   PubMed=26589293;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=34339474;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Virology: Highly susceptible to infection by SARS coronavirus (SARS-CoV) (PubMed=15316659).
CC   Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=34339474).
CC   Doubling time: ~1 week (DSMZ=ACC-504).
CC   HLA typing: A*02:01,11:01; B*07:02,51:01; C*04:01,07:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=3.68%; Native American=0%; East Asian, North=5.8%; East Asian, South=0%; South Asian=0%; European, North=50.95%; European, South=39.58% (PubMed=30894373).
CC   Derived from site: In situ; Colon, sigmoid; UBERON=UBERON_0001159.
ST   Source(s): DSMZ; PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8,12
ST   D16S539: 11,13
ST   D18S51: 17
ST   D19S433: 13,17
ST   D21S11: 28,29
ST   D2S1338: 21,25
ST   D3S1358: 17
ST   D5S818: 11
ST   D7S820: 11,12
ST   D8S1179: 12
ST   FGA: 25
ST   Penta D: 10
ST   Penta E: 10,12
ST   TH01: 6,8
ST   TPOX: 8
ST   vWA: 16,18
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 30
//
RX   PubMed=15316659; DOI=10.1007/s00018-004-4222-9;
RA   Cinatl J. Jr., Hoever G., Morgenstern B., Preiser W., Vogel J.-U.,
RA   Hofmann W.-K., Bauer G., Michaelis M., Rabenau H.F., Doerr H.-W.;
RT   "Infection of cultured intestinal epithelial cells with severe acute
RT   respiratory syndrome coronavirus.";
RL   Cell. Mol. Life Sci. 61:2100-2112(2004).
//
RX   PubMed=19003396; DOI=10.1023/A:1008131428992;
RA   Farrell T.M., Pettengill O.S., Longnecker D.S., Cate C.C., Cohn K.H.;
RT   "Growing colorectal tumors: minimizing microbial and stromal
RT   competition and assessing in vitro selection pressures.";
RL   Cytotechnology 34:205-211(2000).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=34339474; DOI=10.1371/journal.pone.0255622;
RA   Pommerenke C., Rand U., Uphoff C.C., Nagel S., Zaborski M., Hauer V.,
RA   Kaufmann M., Meyer C., Denkmann S.A., Riese P., Eschke K., Kim Y.,
RA   Safranko Z.M., Kurolt I.-C., Markotic A., Cicin-Sain L., Steenpass L.;
RT   "Identification of cell lines CL-14, CL-40 and CAL-51 as suitable
RT   models for SARS-CoV-2 infection studies.";
RL   PLoS ONE 16:E0255622-E0255622(2021).
//